GSPT2抗体;GSPT2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: PC3 cell lysate, Primary antibody: P10202(GSPT2 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 6 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10202(GSPT2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10202(GSPT2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of GSPT2 Antibody**

GSPT2 (G1 to S Phase Transition 2), also known as eukaryotic translation termination factor eRF3b, is a member of the GSPT protein family involved in translational regulation and cell cycle progression. It shares homology with GSPT1 (eRF3a) and plays a role in ribosome-mediated protein synthesis termination by interacting with eRF1 to hydrolyze GTP during the release of nascent polypeptides. GSPT2 is implicated in regulating G1/S phase transition, apoptosis, and cellular stress responses.

Antibodies targeting GSPT2 are essential tools for studying its expression, localization, and function in physiological and pathological contexts. Research highlights its potential role in cancer, where altered expression of GSPT2 correlates with tumor progression, drug resistance, and survival outcomes. For example, GSPT2 degradation has been explored as a therapeutic strategy in hematologic malignancies using cereblon-modulating agents like immunomodulatory drugs (IMiDs).

GSPT2-specific antibodies enable detection via techniques such as Western blot, immunohistochemistry, and immunofluorescence, aiding in mechanistic studies of its involvement in translation control, cell cycle dysregulation, and disease pathways. These antibodies also support the development of targeted therapies, particularly in cancers reliant on GSPT2-dependent proteostasis.